(Bloomberg) -- Israel's largest venture capital investor in life sciences, AMoon, boosted the size of its biggest fund to $750 million after demand for new health-care technology rose during the coronavirus pandemic.
Existing and new investors contributed to the fund, known as AMoon II, which topped out at $660 million last year, co-founder and managing partner Yair Schindel said in an interview. AMoon partnered with Credit Suisse Group AG to secure the new funds.
Investors “mostly panicked” at the onset of the pandemic, deciding to wait out the economic fallout, Schindel said. But after about a month, “something defrosted and then they came back with a vengeance.”
Recent U.S. regulatory changes such as those that make it easier for patients to see doctors remotely and be reimbursed for those virtual visits are driving investor interest in health-care startups, according to Tomer Berkovitz, partner and chief financial officer at the firm. Venture capital investment in health-tech startups reached $5.4 billion in the first half and is on track to top the record of $8.2 billion set in 2018, according to a report by Rock Health.
So far, AMoon has invested about $200 million from the fund in nine companies, and is in advanced talks with another three, Berkovitz said. AMoon expects to complete the initial investments in the portfolio within two years, bringing the total number of companies to around 20, he said.
The fund invests between $10 million and $25 million for startups, and reserves capital for subsequent investment rounds, Berkovitz said.
©2020 Bloomberg L.P.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
